Resumen de acción KILITCH
Kilitch Drugs (India) Limited se dedica al desarrollo y la explotación de negocios farmacéuticos en India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Competidores de Kilitch Drugs (India) Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | ₹330.55 |
| 52 Week High | ₹470.00 |
| 52 Week Low | ₹175.00 |
| Beta | 0.30 |
| 1 Month Change | -9.09% |
| 3 Month Change | -24.51% |
| 1 Year Change | 55.08% |
| 3 Year Change | 103.04% |
| 5 Year Change | 93.13% |
| Change since IPO | 158.85% |
Noticias y actualizaciones recientes
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05
Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump
Feb 02We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease
Jan 30Recent updates
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump
Feb 02We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease
Jan 30Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings
Nov 17Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why
Sep 23These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors
May 05Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today
Apr 08These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 13Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03
Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?
Aug 20Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jul 16Rentabilidad de los accionistas
| KILITCH | IN Pharmaceuticals | Mercado IN | |
|---|---|---|---|
| 7D | -6.9% | -3.4% | -3.7% |
| 1Y | 55.1% | 53.6% | 38.4% |
Rentabilidad vs. Industria: KILITCH superó a la industria Indian Pharmaceuticals, que obtuvo un rendimiento del 53.6% el año pasado.
Rentabilidad vs. Mercado: KILITCH superó al mercado Indian, que obtuvo un rendimiento del 46.4% el año pasado.
Volatilidad de los precios
| KILITCH volatility | |
|---|---|
| KILITCH Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.8% |
| 10% least volatile stocks in IN Market | 4.2% |
Precio estable de las acciones: El precio de las acciones de KILITCH ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de KILITCH (6%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1978 | 153 | Mukund Mehta | www.kilitch.com |
Kilitch Drugs (India) Limited se dedica al desarrollo y la explotación de negocios farmacéuticos en India. La empresa ofrece productos parenterales y nasales, incluidos gastroenterológicos, antiinflamatorios, anticonvulsivos/antiepilépticos, antipalúdicos, aminoglucósidos, antibacterianos, antihipertensivos, antiinfecciosos, de diagnóstico, simpaticomiméticos, anestésicos locales, neurotónicos, estimulantes uterinos, preparados externos, antiinflamatorios no esteroideos, oncológicos, oftálmicos y otros medicamentos, así como vacunas y productos veterinarios en forma de ampollas líquidas, viales y polvos secos inyectables. Sus productos parenterales y nasales también incluyen suplementos de hierro para el tratamiento de la anemia y gotas nasales dosificadas, así como los productos Klavmox y Onecef.
Resumen de fundamentos de Kilitch Drugs (India) Limited
| Estadísticas fundamentales de KILITCH | |
|---|---|
| Capitalización bursátil | ₹5.21b |
| Beneficios(TTM) | ₹145.71m |
| Ingresos (TTM) | ₹1.55b |
36.9x
Ratio precio-beneficio (PE)3.5x
Ratio precio-ventas (PS)¿Está KILITCH sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de KILITCH | |
|---|---|
| Ingresos | ₹1.55b |
| Coste de los ingresos | ₹804.09m |
| Beneficio bruto | ₹746.22m |
| Otros gastos | ₹600.52m |
| Beneficios | ₹145.71m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 30, 2024
| Beneficios por acción (BPA) | 9.06 |
| Margen bruto | 48.13% |
| Margen de beneficio neto | 9.40% |
| Ratio deuda/patrimonio | 17.2% |
¿Cómo se ha desempeñado KILITCH a largo plazo?
Ver rendimiento histórico y comparativa